Related Experiment Video

Updated: Jun 5, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer

Elisa Giovannetti1, Lale Erdem, Efnan Olcay

  • 1Department Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

Frontiers in Bioscience (Landmark Edition)
|January 4, 2011
PubMed

Insights

Identifying genetic variations (polymorphisms) in genes like EGFR may help predict treatment response and toxicity in non-small-cell lung cancer (NSCLC) patients receiving targeted therapies.

Area of Science:

  • Oncology
  • Pharmacogenomics

Background:

  • Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with chemotherapy offering limited therapeutic advancement and significant toxicity.
  • Targeted therapies, particularly those inhibiting the epidermal-growth-factor receptor (EGFR), show promise but their efficacy and tolerability are not fully explained by current biomarkers.
  • Novel biomarkers are crucial for optimizing anti-EGFR treatment strategies in NSCLC.

Purpose of the Study:

  • To explore the role of germline polymorphisms in genes such as EGFR, AKT1, and ABCG2 as potential predictive and prognostic biomarkers for NSCLC patients undergoing anti-EGFR therapy.
  • To address the inconsistencies in previous findings and emphasize the need for prospective studies to validate the clinical utility of these genetic markers.

Main Methods:

  • Review and analysis of existing literature on germline polymorphisms in EGFR, AKT1, and ABCG2 in relation to clinical outcomes and toxicity in NSCLC patients.
  • Highlighting the need for prospective studies to evaluate the prognostic and predictive value of these polymorphisms.

Main Results:

  • Germline polymorphisms in EGFR, AKT1, and ABCG2 have been associated with varying outcomes and toxicity profiles in NSCLC patients treated with anti-EGFR agents.
  • Existing findings are often inconsistent, necessitating further investigation.

Conclusions:

  • Germline polymorphisms represent a promising area for identifying novel biomarkers to personalize anti-EGFR therapy in NSCLC.
  • Prospective studies are essential to confirm the predictive and prognostic roles of these genetic variations and to investigate their correlation with drug concentration and activity.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...